Cyclerion Therapeutics (NASDAQ:CYCN) and SCYNEXIS (NASDAQ:SCYX) Financial Survey

SCYNEXIS (NASDAQ:SCYX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

This table compares SCYNEXIS and Cyclerion Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60 million	2.15	-$8.61 million	($2.09)	-2.13
Cyclerion Therapeutics	$2.07 million	7.89	-$3.53 million	($1.66)	-2.10

Cyclerion Therapeutics has lower revenue, but higher earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SCYNEXIS and Cyclerion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-44.15%	-32.61%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Insider & Institutional Ownership

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for SCYNEXIS and Cyclerion Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1	0	2	0	2.33
Cyclerion Therapeutics	1	0	0	0	1.00

SCYNEXIS presently has a consensus target price of $33.00, suggesting a potential upside of 641.41%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Cyclerion Therapeutics.

Risk & Volatility

SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.